



InCellTx

# THE PROBLEM

**+150,000**  
Transplants per year in the world  
and 65% are renal



**50%**  
Of kidney transplant patients, 10% die within 10 years due to ineffective treatments with immunosuppressants that inhibit the activity of the entire immune system to prevent rejection of transplanted organs.

## OUR SOLUTION

Specific cellular therapy based on

**Tregs**

Inhibits the immune response to transplantation

Organ and tissue rejection.

Autoimmunity. Inflammation.

The patient's Treg cells are "educated" to specifically compress


**TRL3**

Pre- Gotomarket

## MARKET



Global



USA and Mexico

Regulatory T cell therapy	
2023	USD 1.02 billions



Market for immunosuppressive drugs in patients with kidney transplants

## FOUNDING TEAM



**Gloria Soldevila, PhD**  
Founding researcher  
Titular C  
(25 years UNAM)



**Evelyn Álvarez Salazar, PhD**  
Co-founder, Inventor



**Roxana Olguín Alor, PhD**  
Co-founder  
Quality management



**Arimelek Cortés, PhD**  
Co-founder, Inventor



InCellTx

Immune balance for health



**Saúl Arteaga, PhD**  
Co-founder, Inventor

## Scientific advisors



**Joaquim Vives, PhD**  
Banc de Sang i Teixits  
of Catalunya,  
Barcelona España



**Alejandro Madrigal, M.D. PhD**  
Tec Monterrey  
University College UK



**Luis Eduardo Buenrostro, M.D.**  
INCMN Salvador  
Zubirán Mexico



**Josefina Alberú, PhD**  
Tec Monterrey Mexico

## INVESTMENT

Stage 1 Fundraising

**USD 1,836,450 millions**

Funding to complete the preclinical phase and obtain permission to start the clinical phase

Technological development	USD 1,455,000 (79%)
Specialized advice and regulatory expenses	USD 139,450 (7.5%)
Working capital (OPEX)	USD 243,500 (13.5%)

In the next 18 months

- 1 Scaling up cell production (54%)
- 2 GMP validation of the cellular product (39%)
- 3 Cofepris approval (7%)

**Contact:**

Francisco Lozano Martínez  
flozano@newgenesis.cl

Raúl Vázquez Cassani  
rvazquez@newgenesis.cl